GlobeNewswire

Ballast Point Brewing to Open in Downtown Disney® District at the Disneyland® Resort

Dela

Award-winning Southern California craft brewer to open in late 2018 with a restaurant, brewery and beer garden

Opening marks Downtown Disney® District's first-ever on-site brewery

SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- San Diego-based Ballast Point®, a pioneer in the craft beer industry and one of the nation's leading craft breweries known for high-quality, award-winning and innovative beers, today announced the opening of a brewery, tasting room and kitchen in the Downtown Disney® District at the Disneyland® Resort. The opening marks the first-ever brewery for Downtown Disney. Opening in late 2018, the 7,000-sq. ft. space will house a three-barrel "research and development" brewery, New American restaurant and outdoor beer garden. This will be Ballast Point's first location in Orange County and seventh in Southern California.

"As one of Southern California's premier brewers, for the team at Ballast Point, we couldn't be more honored to work with such an icon in our great state and become the first brewer at Downtown Disney," said Marty Birkel, president of Ballast Point Brewing Company. "We hope SoCal locals and visitors alike will enjoy the wonderful atmosphere, seasonal cuisine, and good cheer (and beer) of our signature tap room experience that we plan to bring to Disney."
"We are thrilled to welcome Ballast Point to Downtown Disney," said Patrick Finnegan, vice president of Disney California Adventure and Downtown Disney. "Our guests are constantly asking for new and innovative dining experiences, and Ballast Point's selection of award-winning beers, locally inspired cuisine and friendly atmosphere make them a perfect fit."

Along with its beers, the restaurant's menu will also offer a taste of San Diego with some of its most popular dishes from its brew pubs, including Baja-style fish tacos and a house-made pretzel with beer mustard. Similar to Ballast Point's brewing philosophy, the kitchen will only source the best possible ingredients, including steroid and antibiotic-free proteins, line-caught fish and local produce when available. The kitchen will feature a seasonally inspired menu, with a focus on cuisine that not only pairs well with the vast selection of beers, but incorporates them in the recipes. The location will also offer a children's menu, along with gluten-free and vegetarian options for guests.

The location will be family-friendly, offering an outdoor patio and large-party, cabana style seating, and visitors 21+ can enjoy many of Ballast Point's iconic beers including its flagship and award-winning Sculpin® IPA, as well as exclusive, custom, limited-edition beers available only at the Downtown Disney location. Known for its unrelenting commitment to quality, unique flavor profiles and a desire to bring great tasting beer to consumers across the country, Ballast Point has been dedicated to the craft of brewing for more than 20 years.

The new Downtown Disney location further extends Ballast Point's brand presence in Southern California and will introduce its quality, great-tasting beer to visitors from around the country and the world. Ballast Point currently operates six tasting room locations in California, including Long Beach and Little Italy in San Diego, and a new brewery and tasting room in Daleville, Virginia. Coming soon, the brewer will also open a brewery and kitchen in Chicago - its first in the Midwest.

About Ballast Point 
What started in 1996 as a small group of home brewers who simply wanted to make great beer evolved into the team of adventurers known today as Ballast Point. From bringing a hoppy twist to a porter, or adding four types of malt to its amber ale, to creating the breakthrough gold-medal winning Sculpin IPA, the San Diego-based company is known for adding its own touch and asking if there's a better way. Now an internationally recognized leader in the craft brewing industry with 7 brewery locations in California and Virginia, the company makes over 50 styles of beer and distributes to 49 states and 17 countries internationally. For more information, visit www.ballastpoint.com.

About Constellation Brands
Constellation Brands (NYSE:STZ) (NYSE:STZ.B), a Fortune 500® company, is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, Italy and Canada. Constellation is the No. 3 beer company in the U.S. with high-end, iconic imported brands such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. The company's beer portfolio also includes Ballast Point, one of the most awarded craft brewers in the U.S. In addition, Constellation is the world leader in premium wine, selling great brands that people love, including Robert Mondavi, Clos du Bois, Kim Crawford, Meiomi, Mark West, Franciscan Estate, Ruffino and The Prisoner. The company's premium spirits brands include SVEDKA Vodka, Casa Noble Tequila and High West Whiskey.

Based in Victor, N.Y., the company believes that industry leadership involves a commitment to brand building, our trade partners, the environment, our investors and to consumers around the world who choose our products when celebrating big moments or enjoying quiet ones. Founded in 1945, Constellation has grown to become a significant player in the beverage alcohol industry with more than 100 brands in its portfolio, about 40 facilities and approximately 9,000 talented employees. We express our company vision: to elevate life with every glass raised. To learn more, visit www.cbrands.com.

MEDIA CONTACT :
Jennifer Dohm
jennifer.dohm@cbrands.com

Photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/09a42ba2-d176-417c-8b8b-15aa1f5fd933 
http://www.globenewswire.com/NewsRoom/AttachmentNg/0d9987f1-8726-493c-93bd-6a7c84846059 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Constellation Brands, Inc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum